Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 11
Submit an article Journal homepage
1,704
Views
41
CrossRef citations to date
0
Altmetric
Original Research

A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

Dedong Caoa Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, ChinaCorrespondence[email protected]
View further author information
,
Huilin Xub Department of Oncology, The Fifth Hospital of WuHan, WuHan, Hubei, ChinaView further author information
,
Ximing Xua Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, ChinaView further author information
,
Tao Guoc Department of Hematology, The Union Hospital, Tongji Medical College, HuaZhong University of Science and Technology, WuHan, Hubei, China;d Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaView further author information
&
Wei Gea Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, ChinaView further author information
Article: e1507262 | Received 18 Apr 2018, Accepted 29 Jul 2018, Published online: 20 Aug 2018

Related Research Data

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies.
Source: Frontiers Media S.A.

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.